NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders and life-threatening pulmonary conditions. The company entered public markets through a SPAC merger with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2018 targeting the healthcare and life sciences sector. The Form 10-Q filed in November 2018 under accession number 0001654954-18-012244 represents an early quarterly filing in the company's public reporting history. NRXP sits within the specialty pharmaceuticals and biotech segment, a sector that has attracted significant SPAC activity in recent years. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on NRXP and hundreds of other SPAC transactions.